Overview
- An investor class action was filed in early May on behalf of those who bought Immutep American Depositary Receipts during the alleged fraud period, claiming the company and certain officers made false or misleading statements about the TACTI‑004 Phase III trial.
- The complaint says an independent data monitoring committee recommended stopping the TACTI‑004 study after a planned interim futility analysis, which triggered a roughly 83% one‑day drop in Immutep ADRs when the decision became public.
- Plaintiffs point to public filings that described the trial as showing strong operational progress in late January and say internal data known to the company made that description false or reckless; those claims remain allegations that must be proved in discovery.
- Several plaintiff firms are soliciting investors and warn that shareholders who want to seek lead‑plaintiff status must file papers by July 6, 2026, a deadline that will shape who directs the litigation and the pace of discovery.
- If the case moves forward, liability and damages will likely depend on internal trial documents and expert analysis, and the suit underscores how NASDAQ‑listed ADRs let U.S. courts hear claims against foreign biotech companies.